Maegim한국어

프로티나

468530KOSDAQSector: Pharma & Biotech
₩21,750 0.00%Market cap ₩240.0BAs of Jul 21, 2026 close · updated once daily
C
Grade C41.8 ptsTop 68% of 2,523 stocks
Financial strength
53.3
Price attractiveness
28.7

As of Jul 21, 2026 close · This grade is not a buy/sell recommendation — it is information mechanically scored from public data using a fixed formula.

Growth momentum not rated — will be included automatically as data accumulates

1

Financial strength

53.3
How much debt does it carry relative to equity?
Debt-to-equity ratio
11.9%
Above median · Top 14% in sector
Sector median 51.5%
Can it cover what's due within a year?
Current ratio
1515.1%
Above median · Top 9.6% in sector
Sector median 191.3%
How much of revenue becomes profit?
Operating margin
-385.2%
Below median · Top 87.9% in sector
Sector median -2.3%
How much did it earn on its own capital?
ROE (return on equity)
-31.8%
Below median · Top 75.4% in sector
Sector median -4.5%

Source filing: annual report (separate) — view original

3

Price attractiveness

28.7
Is the price expensive relative to earnings?
P/E (price-to-earnings)
Loss-making (P/E not computable)
Below median · Top 58.3% in sector
Sector median P/E of profitable peers 14.4x · 57% loss-making
Is the price expensive relative to book value?
P/B (price-to-book)
8.46x
Below median · Top 84.3% in sector
Sector median 1.39x

Valuation uses the Jul 21, 2026 close and market cap

Grade distribution of 248 stocks in Pharma & Biotech

S1A52B66C51D61F15